Ibutilide: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Antiarrhythmics]] | *Type: [[Antiarrhythmics]] | ||
*Dosage Forms: | *Dosage Forms:IV 1mg/10mL | ||
*Common Trade Names: | *Common Trade Names: Corvert | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 10: | Line 10: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established'' | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Use in pregnancy may be considered, but data is sparse | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Not recoemmended | ||
*Renal Dosing | *Renal Dosing: none | ||
*Hepatic Dosing: none | |||
*Hepatic Dosing | |||
== Indications == | ==Indications== | ||
*Rapid conversion of recent-onset A-fib/flutter to NSR | *Rapid conversion of recent-onset A-fib/flutter to NSR | ||
| Line 32: | Line 29: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2-12h | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: Mostly urine | ||
*Mechanism of Action: Class III - Prolongs AP and refractory period | *Mechanism of Action: Class III - Prolongs AP and refractory period | ||
=== Kinetics === | ===Kinetics=== | ||
*Onset of action = 20-30min | *Onset of action = 20-30min | ||
*Duration of action = 24hr | *Duration of action = 24hr | ||
| Line 48: | Line 45: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] [[Category:Cardiology]] | ||
Latest revision as of 20:30, 22 September 2019
General
- Type: Antiarrhythmics
- Dosage Forms:IV 1mg/10mL
- Common Trade Names: Corvert
Adult Dosing
- Loading dose = 1mg IV in 50mL D5W over 10min (wt>60kg)
- Loading dose = 0.01mg/kg IV in 50mL D5W over 10min (wt<60kg)
- Dose may be repeated 10min after completion of 1st dose
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: Use in pregnancy may be considered, but data is sparse
- Lactation risk: Not recoemmended
- Renal Dosing: none
- Hepatic Dosing: none
Indications
- Rapid conversion of recent-onset A-fib/flutter to NSR
Contraindications
- Allergy to class/drug
Adverse Reactions
- QT prolongation, V-tach, torsades
- Observe for 4hr after infusion
Pharmacology
- Half-life: 2-12h
- Metabolism: Hepatic
- Excretion: Mostly urine
- Mechanism of Action: Class III - Prolongs AP and refractory period
Kinetics
- Onset of action = 20-30min
- Duration of action = 24hr